{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T01:21:35Z","timestamp":1794878495493,"version":"4.9.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The development of generic versions of Onivyde\u00ae (irinotecan liposome injection) requires a reliable and discriminative\n                    <jats:italic>in vitro<\/jats:italic>\n                    release test (IVRT) to ensure product quality and support regulatory approval. Conventional dialysis-based IVRT often is limited in maintaining sink conditions and is affected by membrane-related variability and batch inconsistency. To overcome these challenges, we developed an IVRT using Bio-Beads SM-2 Resin (BioBeads), which rapidly adsorb released free irinotecan via hydrophobic interactions. Key parameters, including BioBeads concentration, agitation speed and angle, temperature, and formulation concentration, were systematically optimized. Identified optimized conditions were 50\u00a0mg\/mL BioBeads, vertical rotation at 10\u00a0rpm, 25\u00b0C, and an Onivyde\u00ae concentration of 45\u00a0\u00b5g\/mL. Under these conditions, the method achieved\u2009&gt;\u200990% drug release within 24\u00a0h with minimal liposomal disruption. Among all parameters, mechanical agitation had the greatest impact on release kinetics by promoting liposomal destabilization and cholesterol depletion. Using the similarity factor (f2) as a quantitative criterion, the method demonstrated high reproducibility and effectively distinguished between non-stressed and stressed formulations. Compared to dialysis-based approaches, this method more effectively maintains sink conditions, eliminates membrane-related diffusion limitations, and simplifies sample handling by avoiding separation steps. Overall, the BioBeads-based IVRT offers a practical, robust, and sensitive platform for accelerated release testing and quality control of liposomal irinotecan, with strong potential for use in generic drug development and regulatory evaluation.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1208\/s12248-026-01222-1","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T20:46:26Z","timestamp":1773434786000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Development of an In Vitro Release Test to Characterize Onivyde\u00ae Using Bio-Beads SM-2 Resin"],"prefix":"10.1208","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3389-1829","authenticated-orcid":false,"given":"Vivian","family":"Juang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9411-621X","authenticated-orcid":false,"given":"May Thazin","family":"Phoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0675-9950","authenticated-orcid":false,"given":"Hsiu-Wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6802-3397","authenticated-orcid":false,"given":"Lei","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8901-2516","authenticated-orcid":false,"given":"Xinye","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3873-7864","authenticated-orcid":false,"given":"Ji","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8023-8080","authenticated-orcid":false,"given":"Anna","family":"Schwendeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"issue":"3","key":"1222_CR1","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1208\/s12248-017-0049-9","volume":"19","author":"M Kapoor","year":"2017","unstructured":"Kapoor M, Lee SL, Tyner KM. Liposomal Drug Product Development and Quality: Current US Experience and Perspective. AAPS J. 2017May 1;19(3):632\u201341.","journal-title":"AAPS J"},{"key":"1222_CR2","doi-asserted-by":"crossref","unstructured":"Large DE, Abdelmessih RG, Fink EA, Auguste DT. Liposome composition in drug delivery design, synthesis, characterization, and clinical application. Advanced Drug Delivery Reviews. 2021 Sept 1;176:113851.","DOI":"10.1016\/j.addr.2021.113851"},{"issue":"236","key":"1222_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2023.115751","volume":"30","author":"S Giordani","year":"2023","unstructured":"Giordani S, Marassi V, Zattoni A, Roda B, Reschiglian P. Liposomes characterization for market approval as pharmaceutical products: Analytical methods, guidelines and standardized protocols. J Pharm Biomed Anal. 2023Nov;30(236):115751.","journal-title":"J Pharm Biomed Anal"},{"key":"1222_CR4","unstructured":"U.S. Food and Drug Administration. ONIVYDE (irinotecan liposome injection) [package insert] [Internet]. 2024. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/207793s016lbl.pdf.\u00a0Accessed 6 Apr 2025."},{"key":"1222_CR5","unstructured":"Ipsen Biopharm Ltd. PRESS RELEASE: Ipsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen in first-line metastatic pancreatic ductal adenocarcinoma [Internet]. 2023. Available from: https:\/\/www.ipsen.com\/us\/press-releases\/ipsen-announces-u-s-fda-submission-acceptance-of-its-supplemental-new-drug-application-for-onivyde-regimen-in-first-line-metastatic-pancreatic-ductal-adenocarcinoma\/. Accessed 22 Nov 2023."},{"issue":"6","key":"1222_CR6","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1158\/0008-5472.CAN-05-4007","volume":"66","author":"DC Drummond","year":"2006","unstructured":"Drummond DC, Noble CO, Guo Z, Hong K, Park JW, Kirpotin DB. Development of a Highly Active Nanoliposomal Irinotecan Using a Novel Intraliposomal Stabilization Strategy. Cancer Res. 2006Mar 15;66(6):3271\u20137.","journal-title":"Cancer Res"},{"key":"1222_CR7","unstructured":"Hong K, Drummond DC, Kirpoti D. United States Patent Application Publication US 2016\/0030341A1. 2016."},{"key":"1222_CR8","unstructured":"USFDA Draft Guidance on Irinotecan Hydrochloride (Recommended Feb 2022) [Internet]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/psg\/PSG_207793.pdf. Accessed 29 Dec 2023."},{"issue":"59","key":"1222_CR9","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.yrtph.2010.09.021","volume":"1","author":"H Schellekens","year":"2011","unstructured":"Schellekens H, Klinger E, M\u00fchlebach S, Brin JF, Storm G, Crommelin DJA. The therapeutic equivalence of complex drugs. Regul Toxicol Pharmacol. 2011Feb;1(59):176\u201383.","journal-title":"Regul Toxicol Pharmacol"},{"key":"1222_CR10","unstructured":"European Medicines Agency (EMA). Data requirements for intravenous liposomal products developed with reference to an innovator liposomal product - Scientific guideline | European Medicines Agency (EMA) [Internet]. 2013. Available from: https:\/\/www.ema.europa.eu\/en\/data-requirements-intravenous-liposomal-products-developed-reference-innovator-liposomal-product-scientific-guideline. Accessed 6 Apr 2025."},{"key":"1222_CR11","unstructured":"U.S. Food and Drug Administration. Liposome Drug Products: Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation [Internet]. 2018. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/liposome-drug-products-chemistry-manufacturing-and-controls-human-pharmacokinetics-and. Accessed 1 Feb 2024."},{"issue":"120","key":"1222_CR12","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ejps.2018.05.004","volume":"30","author":"L Nothnagel","year":"2018","unstructured":"Nothnagel L, Wacker MG. How to measure release from nanosized carriers? Eur J Pharm Sci. 2018July;30(120):199\u2013211.","journal-title":"Eur J Pharm Sci"},{"issue":"6","key":"1222_CR13","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1208\/s12248-017-0142-0","volume":"19","author":"D Solomon","year":"2017","unstructured":"Solomon D, Gupta N, Mulla NS, Shukla S, Guerrero YA, Gupta V. Role of In Vitro Release Methods in Liposomal Formulation Development: Challenges and Regulatory Perspective. AAPS J. 2017Nov 1;19(6):1669\u201381.","journal-title":"AAPS J"},{"key":"1222_CR14","doi-asserted-by":"crossref","unstructured":"Anand O, Yu LX, Conner DP, Davit BM. Dissolution testing for generic drugs: an fda perspective.\u00a0AAPS J. 2011;13(3):328\u201335.","DOI":"10.1208\/s12248-011-9272-y"},{"issue":"165","key":"1222_CR15","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ejpb.2021.05.008","volume":"1","author":"M Goel","year":"2021","unstructured":"Goel M, Leung D, Famili A, Chang D, Nayak P, Al-Sayah M. Accelerated in vitro release testing method for a long-acting peptide-PLGA formulation. Eur J Pharm Biopharm. 2021Aug;1(165):185\u201392.","journal-title":"Eur J Pharm Biopharm"},{"issue":"7","key":"1222_CR16","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1111\/j.2042-7158.2012.01482.x","volume":"64","author":"J Shen","year":"2012","unstructured":"Shen J, Burgess DJ. Accelerated in vitro release testing methods for extended release parenteral dosage forms. J Pharm Pharmacol. 2012;64(7):986\u201396.","journal-title":"J Pharm Pharmacol"},{"issue":"84","key":"1222_CR17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0168-3659(02)00294-8","volume":"5","author":"JA Shabbits","year":"2002","unstructured":"Shabbits JA, Chiu GNC, Mayer LD. Development of an in vitro drug release assay that accurately predicts in vivo drug retention for liposome-based delivery systems. J Control Release. 2002Dec;5(84):161\u201370.","journal-title":"J Control Release"},{"issue":"8","key":"1222_CR18","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1021\/mp400154a","volume":"10","author":"S Modi","year":"2013","unstructured":"Modi S, Anderson BD. Determination of Drug Release Kinetics from Nanoparticles: Overcoming Pitfalls of the Dynamic Dialysis Method. Mol Pharmaceutics. 2013Aug 5;10(8):3076\u201389.","journal-title":"Mol Pharmaceutics"},{"issue":"1","key":"1222_CR19","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1208\/s12248-016-9958-2","volume":"19","author":"W Yuan","year":"2017","unstructured":"Yuan W, Kuai R, Dai Z, Yuan Y, Zheng N, Jiang W, et al. Development of a Flow-Through USP-4 Apparatus Drug Release Assay to Evaluate Doxorubicin Liposomes. AAPS J. 2017Jan 1;19(1):150\u201360.","journal-title":"AAPS J"},{"issue":"4","key":"1222_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14040883","volume":"14","author":"SZ Alshawwa","year":"2022","unstructured":"Alshawwa SZ, Kassem AA, Farid RM, Mostafa SK, Labib GS. Nanocarrier drug delivery systems: characterization, limitations, future perspectives and implementation of artificial intelligence. Pharmaceutics. 2022;14(4):883.","journal-title":"Pharmaceutics"},{"issue":"315","key":"1222_CR21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jconrel.2019.09.016","volume":"10","author":"M Yu","year":"2019","unstructured":"Yu M, Yuan W, Li D, Schwendeman A, Schwendeman SP. Predicting drug release kinetics from nanocarriers inside dialysis bags. J Control Release. 2019Dec;10(315):23\u201330.","journal-title":"J Control Release"},{"issue":"8","key":"1222_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13081313","volume":"13","author":"Y Kim","year":"2021","unstructured":"Kim Y, Park EJ, Kim TW, Na DH. Recent progress in drug release testing methods of biopolymeric particulate system. Pharmaceutics. 2021;13(8):1313.","journal-title":"Pharmaceutics"},{"key":"1222_CR23","unstructured":"Bio-Rad Laboratories. Bio-Beads SM-2 Resin | Bio-Rad [Internet]. Available from: https:\/\/www.bio-rad.com\/en-us\/product\/bio-beads-sm-2-resin. Accessed 17 Jan 2024."},{"issue":"31","key":"1222_CR24","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jes.2014.12.008","volume":"1","author":"A Ahmad","year":"2015","unstructured":"Ahmad A, Siddique JA, Laskar MA, Kumar R, Mohd-Setapar SH, Khatoon A, et al. New generation Amberlite XAD resin for the removal of metal ions: A review. J Environ Sci. 2015May;1(31):104\u201323.","journal-title":"J Environ Sci"},{"key":"1222_CR25","doi-asserted-by":"crossref","unstructured":"Musshoff F. Drugs of abuse: solid-phase extraction. In: Wilson ID, editor. Encyclopedia of Separation Science [Internet]. Oxford: Academic Press; 2000. p. 2580\u20132588. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/B0122267702067715. Accessed 24 Apr 2025.","DOI":"10.1016\/B0-12-226770-2\/06771-5"},{"issue":"3\u20134","key":"1222_CR26","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/10408340490888689","volume":"34","author":"TP Rao","year":"2004","unstructured":"Rao TP, Praveen RS, Daniel S. Styrene-Divinyl Benzene Copolymers: Synthesis, Characterization, and Their Role in Inorganic Trace Analysis. Crit Rev Anal Chem. 2004July 1;34(3\u20134):177\u201393.","journal-title":"Crit Rev Anal Chem"},{"issue":"9","key":"1222_CR27","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s00726-023-03302-4","volume":"55","author":"AV Kolesnichenko","year":"2023","unstructured":"Kolesnichenko AV, Kazmina NA, Chistov AA, Vakhrenev RG, Kolesanova EF. Influence of amino acid and N-terminal protection residue structures on peptide p-nitroanilide adsorption on polystyrene-based support. Amino Acids. 2023;55(9):1137\u201340.","journal-title":"Amino Acids"},{"issue":"1","key":"1222_CR28","doi-asserted-by":"publisher","first-page":"16334","DOI":"10.1038\/s41598-020-73522-1","volume":"10","author":"SK Palanirajan","year":"2020","unstructured":"Palanirajan SK, Govindasamy P, Gummadi SN. Polystyrene adsorbents: rapid and efficient surrogate for dialysis in membrane protein purification. Sci Rep. 2020Oct 1;10(1):16334.","journal-title":"Sci Rep"},{"issue":"3","key":"1222_CR29","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1006\/jsbi.1997.3848","volume":"118","author":"JL Rigaud","year":"1997","unstructured":"Rigaud JL, Mosser G, Lacapere JJ, Olofsson A, Levy D, Ranck JL. Bio-Beads: An Efficient Strategy for Two-Dimensional Crystallization of Membrane Proteins. J Struct Biol. 1997Apr 1;118(3):226\u201335.","journal-title":"J Struct Biol"},{"issue":"2","key":"1222_CR30","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/0003-2697(83)90605-X","volume":"130","author":"T Horigome","year":"1983","unstructured":"Horigome T, Sugano H. A rapid method for removal of detergents from protein solution. Anal Biochem. 1983Apr 15;130(2):393\u20136.","journal-title":"Anal Biochem"},{"issue":"669","key":"1222_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.125000","volume":"25","author":"J Gan","year":"2025","unstructured":"Gan J, Juang V, Wang K, Xia Z, Ackermann R, Yu M, et al. Reverse engineering of Onivyde\u00ae \u2013 Irinotecan liposome injection. Int J Pharm. 2025Jan;25(669):125000.","journal-title":"Int J Pharm"},{"key":"1222_CR32","unstructured":"Sigma-Aldrich. Cholesterol Quantification Assay Kit for colorimetric or fluorometric assays Sigma [Internet]. Available from: https:\/\/www.sigmaaldrich.com\/US\/en\/product\/sigma\/cs0005. Accessed 6 Apr 2025."},{"key":"1222_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13101703","volume":"13","author":"J Musel\u00edk","year":"2021","unstructured":"Musel\u00edk J, Komersov\u00e1 A, Kubov\u00e1 K, Matzick K, Skalick\u00e1 B. A critical overview of FDA and EMA statistical methods to compare in vitro drug dissolution profiles of pharmaceutical products. Pharmaceutics. 2021;13:1703.","journal-title":"Pharmaceutics"},{"issue":"667","key":"1222_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.124854","volume":"25","author":"V Juang","year":"2024","unstructured":"Juang V, Gan J, Xia Z, Wang Y, Schwendeman A. Development and optimization of an in vitro release assay for evaluation of liposomal irinotecan formulation. Int J Pharm. 2024Dec;25(667):124854.","journal-title":"Int J Pharm"},{"issue":"3","key":"1222_CR35","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1021\/acs.jctc.8b00933","volume":"15","author":"RX Gu","year":"2019","unstructured":"Gu RX, Baoukina S, Tieleman DP. Cholesterol Flip-Flop in Heterogeneous Membranes. J Chem Theory Comput. 2019Mar 12;15(3):2064\u201370.","journal-title":"J Chem Theory Comput"},{"issue":"592","key":"1222_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.120051","volume":"5","author":"S Maritim","year":"2021","unstructured":"Maritim S, Boulas P, Lin Y. Comprehensive analysis of liposome formulation parameters and their influence on encapsulation, stability and drug release in glibenclamide liposomes. Int J Pharm. 2021Jan;5(592):120051.","journal-title":"Int J Pharm"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01222-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-026-01222-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01222-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T17:35:24Z","timestamp":1774460124000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-026-01222-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":36,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["1222"],"URL":"https:\/\/doi.org\/10.1208\/s12248-026-01222-1","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"3 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by FDA\/HHS, or the U.S. Government.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}],"article-number":"73"}}